SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Diet pills and bottle of diet supplements with measuring tape
GLP-1
Novo’s Wegovy Pill Wins Obesity Approval, Securing Lead in Oral GLP-1 Race
Analysts called the approval a much-needed win for Novo Nordisk, but warned that the company could struggle to grow sales once rival drugs come to market.
December 23, 2025
 · 
2 min read
 · 
Nick Paul Taylor
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Neuroscience
Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial
Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine’s valuation.
December 23, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Abstract creative financial graph with finger clicks on a digital tablet on background, forex and investment concept.
Legal
Investment Banker Accused of Leaking Pharma M&A Secrets in $41M Insider Trading Scheme
The banker allegedly shared details of a series of multibillion-dollar buyouts by companies including AbbVie, GSK and Pfizer.
December 23, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Made in USA, with USA Map. 3D Illustration
Manufacturing
2025: The Year Trump Pushed Manufacturing Into the Spotlight
A push to reshore some drug production and progress in advanced manufacturing technologies have been prominent trends this year, industry leaders say.
December 23, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Money or health. Scale of balance between money, dollar and medicine, pill. Cost of health. Compare of price healthcare and healthy. Seesaw between wealth and healthy. Treatment or savings. Vector.
Drug pricing
Trump Administration Reaches Pricing Agreements with 9 More Drugmakers
Leerink analysts hailed the deals as a sign that President Trump “is unlikely to attack the industry in 2026.”
December 22, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Policy
Disc Shares Slip Amid Report FDA’s Prasad is Skeptical of Bitopertin’s Efficacy
The biologics center director reportedly became personally involved after the team reviewing the rare blood disorder filing asked for an extension to the CNPV-accelerated timeline.
December 22, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Approvals
Cytokinetics Wins FDA Approval, Clearing Way to Challenge BMS in Heart Disease Market
Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos.
December 22, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Checklist
Manufacturing
Big Pharma Pushes FDA To Decouple Inspections From Drug Approval Applications
Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s approach to pre-approval inspections.
December 16, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Traffic light in green color, with the dusk sky in the background.
Manufacturing
FDA’s Manufacturing Designation Could Derisk Mid-Development Manufacturing Changes
The status could support staged transitions to new manufacturing processes, potentially mitigating some risks of high-stakes switches.
December 9, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Illustration of a syringe and medicine bottle with some broken glass
Manufacturing
Biotechs Secure Alternative Fill/Finish Capacity Amid Scrutiny of Novo Site
Following FDA rejections, Regeneron and Scholar Rock are turning to other facilities to clear regulatory logjams created by quality problems at an ex-Catalent facility in Indiana. Novo Nordisk, meanwhile, has been tight-lipped about whether its own FDA applications have been affected.
December 2, 2025
 · 
6 min read
 · 
Nick Paul Taylor
Planning strategy and ways to achieve business goals, searching for new opportunities for high results, direction of career development, the path to great success, man changes direction on signpost.
Manufacturing
As CGT Struggles To Scale, FDA’s New Designation Could Smooth Post-Approval Pivots
Experts suggest the FDA’s Advanced Manufacturing Technologies designation could be a lifeline for improving production processes for approved cell and gene therapies.
November 25, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Dollar Sign with Colorful geometric shapes. Business in trendy riso graph design. Geometry elements with Currency Symbol, abstract risograph print texture style.
C-suite
Eli Lilly Enters Uncharted Territory as Market Cap Nears $1T
The drugmaker’s dominance of the obesity market is fueling predictions that years of growth lie ahead.
November 20, 2025
 · 
5 min read
 · 
Nick Paul Taylor
3d rendering of Radiopharmaceuticals, these are radioactive medications or radioisotopes. These medications can be delivered orally in pill form.
Manufacturing
Surge in Radiopharmaceutical R&D Puts Pressure on Unique Supply Chain
The industry’s ability to generate a return on billions of dollars of investment rests on a heavily regulated supply chain defined by time-pressured logistics.
November 18, 2025
 · 
4 min read
 · 
Nick Paul Taylor
factory of the pharmaceutical industry. pills on the conveyor
Manufacturing
Drugmakers Push FDA To Extend Support to Existing Facilities
Representatives from companies such as Sanofi and Forge Biologics point to the potential for PreCheck to drive activation of idle production capacity and help companies that are already building plants.
November 11, 2025
 · 
4 min read
 · 
Nick Paul Taylor
A panoramic view of the Statue of Liberty framed by heavy clouds just before storm. USA, New York City.
Manufacturing
Generic Drug and API Manufacturers Call for Onshoring Incentives
Having seen Congress spend money to onshore semiconductor production, pharma groups are pushing for similar incentives for domestic drug manufacturing.
November 4, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Load More